Vector Labs Ab03232-10.3 Anti-IL-2 [NARA1], Human IgG1, Fc Silent™, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: NARA1
Heavy Chain Modification: Fc Silent™
Synonyms: IL2; IL-2; TCGF; Interleukin-2; T-cell growth factor; Aldesleukin
Amount: 200 μg
Application Codes Clone: Crystallography; in vivo; in vitro; SPR; FC
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG2a
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format for improved compatibility with existing reagents assays and techniques.
Specificity Statement: The antibody is specific for human IL-2. The antibody binds to a three-dimensional epitope of hIL-2 (residues P34, K35, R38, T41, Q74, and K76). The antibody overlaps with the CD25-binding epitope of IL-2. The antibody does not cross reacts with mouse IL-2.
Application Notes: SPR showed the binding of the antibody to IL-2 prevented further binding of hCD25 to IL-2; the affinity of the antibody to hIL-2 was ~10−9 M. The crystal structure of the Fab fragment in complex with IL-2 was determined. IL-2/antibody complexes preferentially expand CD8+ T and NK cells in vivo while disfavoring CD25+ Tregs in transplantable metastatic melanoma model. This difference was also confirmed by kinetic proliferation studies. The complex IL-2/antibody decreased the tumor growth in mice by increasing the CD8+ T cell responses. The IL-2/antibody complex immunotherapy was also efficacious in a spontaneous melanoma model in mice. The complex Il-2/antibody shows potential as a therapeutic agent as it achieved strong antitumor immune responses (Arenas-Ramirez et al., 2016; PMID: 27903862). In order to prevent in vivo dissociation of the complex IL-2/antibody, NARA1leukin was constructed by integrating IL-2 into the antigen-binding groove on the antibody. The NARA1leukin version showed a longer half-life in vivo and more expansion of CD8+ T and NK cells, with no association with CD25, leading to a stronger antitumor response in B16-F10 murine models (Sahin et al., 2020; PMID: 33353953). The use of hIL-2/NARA1 in combination with Ezh2, an inhibitor of the histone methyltransferase enhancer of zeste homolog 2, showed enhanced tumor control in several mouse models of melanoma (Zingg et al., 2017: PMID: 28746871).

Product Class:	Purified
Clone ID:	NARA1
Heavy Chain Modification:	Fc Silent™
Synonyms:	IL2; IL-2; TCGF; Interleukin-2; T-cell growth factor; Aldesleukin
Amount:	200 μg
Application Codes Clone:	Crystallography; in vivo; in vitro; SPR; FC
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG2a
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format for improved compatibility with existing reagents assays and techniques.
Specificity Statement:	The antibody is specific for human IL-2. The antibody binds to a three-dimensional epitope of hIL-2 (residues P34, K35, R38, T41, Q74, and K76). The antibody overlaps with the CD25-binding epitope of IL-2. The antibody does not cross reacts with mouse IL-2.
Application Notes:	SPR showed the binding of the antibody to IL-2 prevented further binding of hCD25 to IL-2; the affinity of the antibody to hIL-2 was ~10−9 M. The crystal structure of the Fab fragment in complex with IL-2 was determined. IL-2/antibody complexes preferentially expand CD8+ T and NK cells in vivo while disfavoring CD25+ Tregs in transplantable metastatic melanoma model. This difference was also confirmed by kinetic proliferation studies. The complex IL-2/antibody decreased the tumor growth in mice by increasing the CD8+ T cell responses. The IL-2/antibody complex immunotherapy was also efficacious in a spontaneous melanoma model in mice. The complex Il-2/antibody shows potential as a therapeutic agent as it achieved strong antitumor immune responses (Arenas-Ramirez et al., 2016; PMID: 27903862). In order to prevent in vivo dissociation of the complex IL-2/antibody, NARA1leukin was constructed by integrating IL-2 into the antigen-binding groove on the antibody. The NARA1leukin version showed a longer half-life in vivo and more expansion of CD8+ T and NK cells, with no association with CD25, leading to a stronger antitumor response in B16-F10 murine models (Sahin et al., 2020; PMID: 33353953). The use of hIL-2/NARA1 in combination with Ezh2, an inhibitor of the histone methyltransferase enhancer of zeste homolog 2, showed enhanced tumor control in several mouse models of melanoma (Zingg et al., 2017: PMID: 28746871).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews